Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
$40B deal: Teva offers to buy Mylan
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Drugmaker Teva makes $40B bid for rival Mylan
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
US lawmakers push Mylan, Teva over drug pricing probe - www.israelhayom.com
How Mylan tried to keep Teva from selling a generic EpiPen
Teva Makes Hostile Bid To Acquire Mylan
Generic drugmaker Teva makes $40bn offer for rival Mylan
Teva offers to buy rival Mylan for $40 billion | Fortune
Teva responds to Mylan backlash with planned launch of generic EpiPen | Healthcare IT News
Teva Pharmaceutical Industries Ltd. ends its hostile bid for Mylan NV - Pittsburgh Business Times
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Mylan NDEA contamination prompts Teva recall in US
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Mylan board rejects Teva takeover bid
Mylan Rejects Teva Takeover Bid As Too Low | Mint
Teva makes $40B offer for Mylan
Mylan shares soar after takeover proposal
Mylan Should Try Teva On for Size - WSJ
Teva's Copaxone holds its own in wake of Mylan's generic price cut | Fierce Pharma
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
